COVID-19 vaccines: Antibodies decrease faster in older people, report says
| Breaking News Updates | Today Headlines
TORONTO – COVID-19 antibodies are declining much faster than expected in the elderly and those with co-morbidities, according to the latest research on long-term care residents funded by the COVID-19 Immunity Task Force (CITF).
The results, they say, strengthen policy decisions and recommendations regarding the provision of reminders to vulnerable populations.
The synthesis report, based on the results of seven CITF-funded studies, comes as the National Advisory Committee on Immunization (NACI) on Friday broadened its eligibility guidelines to include, among other groups, people aged 70 years and over. Some of the results of the CITF-funded research support earlier studies with similar findings.
CITF, which includes experts from universities across Canada, Chief Public Health Officer Dr. Theresa Tam, NACI, and provincial and territorial representatives, was launched by the Canadian government in April 2020. The organization helps support, harmonize and implement research studies and coordinates with leading scientists, policy makers, hospitals, communities and other partners across Canada.
The report says studies, including one from the University of Toronto, have consistently shown that the amount of antibodies from mRNA vaccines decreases faster than expected in older populations compared to younger people, especially in older people. people living in long-term care homes. Another study from the University of Toronto and another from Montreal also found that longer dosing intervals had a neutral or positive effect on the amount of antibody produced after the second dose.
The seven studies looked at the antibody levels of those who received a two-dose regimen of an mRNA vaccine and found that Moderna and Pfizer were both “very effective at inducing antibodies after the second dose.”
But three of the studies, one from McMaster University, another from Montreal and a third from the Bruyère Institute, found that Moderna produced better results. One research project found that the amount of antibodies produced after an injection of Moderna was higher and lasted longer, while another found that antibody levels decreased much faster in nursing home residents. long lasting after a first dose of Pfizer compared to Moderna. A third study found a stronger immune response in older Moderna recipients.
The Montreal study was also able to show that the serological response four weeks after the second dose was comparable in all three types of mRNA regimens – two doses of Moderna or Pfizer, or a mixture of the two.
Several studies have also reinforced the existing data which showed that age and co-morbidities were major factors in the effectiveness of vaccines.
The report noted that while it is clear that antibody levels eventually decline, there are other factors that also determine a person’s immunity, and antibody levels alone do not give an accurate picture of a person’s ability to fight infection.
“That said, the decrease in antibodies in LTC residents and older Canadians living in the community is so significant compared to younger, healthier Canadians, that a third dose is certainly a safer approach to avoid more. deaths and illnesses, ”the report notes, adding that the findings also illustrated the importance of immunizing all long-term care staff.
“The third dose may help, but some residents may still not achieve an adequate long-term antibody response and therefore other protective measures in LTC homes continue to be of the utmost importance. “
Breaking News Updates World news COVID-19 vaccines: Antibodies decrease faster in older people, report says